Celgene-backed FLX picks CCR4 antagonist for clinical trials

San Francisco (Pixabay)
San Francisco, near where FLX is based

FLX Bio has picked a clinical candidate from its CCR4 antagonist program. The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.

San Francisco, CA-based FLX emerged from Bristol-Myers Squibb’s $800 million takeover of Flexus Biosciences with a pipeline of prospects the Big Pharma decided it could live without. Fundraising rounds totaling $79 million followed, giving FLX the means to move some of its early-stage assets toward the clinic.

FLX475 is set to become first to reach human testing. FLX thinks the drug can disrupt the barrier of regulatory T cells that accumulate around tumors and stop the immune system from performing its cancer killing duties.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“CCR4 represents a key pathway by which tumors recruit regulatory T cells to suppress tumor immunity. By blocking this pathway with a CCR4 antagonist, it may be possible to prevent regulatory T cell recruitment to the tumor site, reduce the number of regulatory T cells in the tumor and importantly, enable immune activation and tumor killing,” Alexander Rudensky, chairman of FLX’s scientific advisory board, said in a statement.

FLX475 is moving toward the clinic on the strength of preclinical data presented by FLX earlier this year. Those results showed FLX’s CCR4 antagonists block the migration of regulatory T cells—in the tumor but not in peripheral tissues—and aid the expansion of activated effector T cells. Adding the CCR4 antagonist to anti-PD-L1 and anti-CD137 antibodies dialed up the tumor-killing effects of these drugs. 

FLX lists the CCR4 antagonist program as the most advanced in its pipeline, despite having started life with a FLT3 and CDK4/6 inhibitor that was already in phase 1. Flexus moved that drug, FLX925, into the clinic just before being bought by Bristol-Myers. And, armed with $50 million in series B funds, FLX was set to take it in into proof-of-concept study in patients with acute myeloid leukemia.

FLX925 has since disappeared from FLX’s pipeline, although a phase 1/1b dose-escalation trial is listed as ongoing on ClinicalTrials.gov.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.